← Back to headlines
Celcuity Projects $2.5B Annual Peak Revenue for Gedatolisib
Celcuity has outlined a potential $2.5 billion in annual peak revenue for its drug gedatolisib, as the company progresses through pivotal clinical milestones and prepares for commercial launch.
26 Mar, 00:16 — 26 Mar, 00:16
Sources
Showing 1 of 1 sources
